Document is current
Any future updates will be listed below
-
Authors
Mateo-Urdiales, Alberto
Fabiani, Massimo
Mayer, Flavia
Sacco, Chiara
Belleudi, Valeria
Da Cas, Roberto
Fotakis, Emmanouil Alexandros
De Angelis, Luigi
Cutillo, Maria
Petrone, Daniele
Morciano, Cristina
Cannone, Andrea
Del Manso, Martina
Riccardo, Flavia
Bella, Antonino
Menniti-Ippolito, Franscesca
Pezzotti, Patrizio
Spila Alegiani, Stefania
Massari, Marco
-
Funding
Funding for this research was provided by:
NextGenerationEU-MUR PNRR (PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007, PE00000007)
- License Information
-
More Information
Article History
Received: 29 February 2024
Accepted: 6 June 2024
First Online: 11 June 2024
Declarations
:
: National Unique Ethics Committee for the evaluation of clinical trials of medicines for human use and medical devices for patients with COVID-19 of the National Institute for Infectious Diseases “Lazzaro Spallanzani” in Rome (ordinance n. 335, 17/05/2021 and n. 399, 02/09/2021) waived the requirement for informed consent and approved the study.
: The authors Chiara Sacco and Emmanouil Alexandros Fotakisare are fellows of the ECDC Fellowship Programme, supported financially by the European Centre for Disease Prevention and Control The views and opinions expressed herein do not state or reflect those of ECDC. ECDC is not responsible for the data and information collation and analysis and cannot be held liable for conclusions or opinions drawn”.
: Not applicable.
: None to be reported by any of the authors.
